Spontaneous ventricular tachyarrhythmias in β2-adrenoceptor transgenic mice in relation to cardiac interstitial fibrosis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 5, 2015, Pages H946-H957

  Nguyen, My Nhan ^a,b   Kiriazis, Helen ^a   Ruggiero, Diego ^a,c   Gao, Xiao Ming ^a,b   Su, Yidan ^a   Jian, Anne ^a   Han, Li Ping ^a,d   McMullen, Julie R ^a,b   Du, Xiao Jun ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MILAN   (Italy)

^d WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Fibrosis; Telemetry; Ventricular tachyarrhythmias; adrenergic receptor

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ALPHA SMOOTH MUSCLE ACTIN; ATENOLOL; ATROPINE; BETA 2 ADRENERGIC RECEPTOR; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CONNEXIN 43; CONNEXIN 45; FIBRONECTIN; GELATINASE A; HYDROXYPROLINE; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED POTASSIUM CHANNEL 2; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED POTASSIUM CHANNEL 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCOLLAGEN; PROCOLLAGEN TYPE I; PROCOLLAGEN TYPE III; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC RECEPTOR BLOCKING; AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CARDIOMYOPATHY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; INFLAMMATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; TELEMETRY; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FIBROSIS; GENETICS; HEART VENTRICLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TACHYCARDIA;

ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ANIMALS; COLLAGEN; FIBROSIS; HEART VENTRICLES; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, ADRENERGIC, BETA-2; TACHYCARDIA;

EID: 84940737605     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00405.2015     Document Type: Article

References (46)

1. Agarwal SK, Simpson RJ Jr, Rautaharju P, Alonso A, Shahar E, Massing M, Saba S, Heiss G. Relation of ventricular premature complexes to heart failure. Am J Cardiol 109: 105–109, 2012
2. Askar SF, Bingen BO, Swildens J, Ypey DL, van der Laarse A, Atsma DE, Zeppenfeld K, Schalij MJ, de Vries AA, Pijnappels DA. Connexin43 silencing in myofibroblasts prevents arrhythmias in myocardial cultures: role of maximal diastolic potential. Cardiovasc Res 93: 434–444, 2012
3. Bathgate RAD, Lekgabe ED, McGuane JT, Su Y, Pham T, Ferraro T, Layfield S, Hannan RD, Thomas WG, Samuel CS, Du XJ. Adenovirusmediated delivery of relaxin reverses cardiac fibrosis. Mol Cell Endo 280: 30–38, 2008
4. Betzenhauser MJ, Marks AR. Ryanodine receptor channelopathies. Pflugers Arch 460: 467–480, 2010
5. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the b2-adrenoceptor. Nature 272-272, 1995
6. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 22: 1136–1143, 2001
7. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-mo mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 39: 30–36, 2002
8. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130: 484–495, 2014
9. Curtis MJ, Hancox JC, Farkas A, Wainwright CL, Stables CL, Saint DA, Clements-Jewery H, Lambiase PD, Billman GE, Janse MJ, Pugsley MK, Ng GA, Roden DM, Camm AJ, Walker MJ. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther 139: 213–248, 2013
10. de Jong S, van Veen TA, van Rijen HV, de Bakker JM. Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol 57: 630–638, 2011
11. De Maria R, Gavazzi A, Caroli A, Ometto R, Biagini A, Camerini F. Ventricular arrhythmias in dilated cardiomyopathy as an independent prognostic hallmark. Am J Cardiol 69: 1451–1457, 1992
12. DeSantiago J, Ai X, Islam M, Acuna G, Ziolo MT, Bers DM, Pogwizd SM. Arrhythmogenic effects of b2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca2 load. Circ Res 102: 1389–1397, 2008
13. Du XJ, Cox HS, Dart AM, Esler MD. Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. Cardiovasc Res 43: 919–929, 1999
14. Du XJ, Feng X, Gao XM, Tan TP, Kiriazis H, Dart AM. If channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol 142: 107–112, 2004
15. Du XJ, Gao XM, Wang B, Jennings GL, Woodcock EA, Dart AM. Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing [1]2-adrenergic receptors in the heart. Cardiovasc Res 48: 448–454, 2000
16. Du XJ, Vincan E, Woodcock DM, Milano CA, Dart AM, Woodcock EA. Response to cardiac sympathetic activation in transgenic mice overexpressing b2-adrenergic receptor. Am J Physiol Heart Circ Physiol 271: H630–H636, 1996
17. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17: 1762–1764, 2003
18. Fujiu K, Nagai R. Fibroblast-mediated pathways in cardiac hypertrophy. J Mol Cell Cardiol 70: 64–73, 2014
19. Gao XM, Agrotis A, Autelitano DJ, Percy E, Woodcock EA, Jennings GL, Dart AM, Du XJ. Sex hormones and cardiomyopathic phenotype induced by cardiac [1]2-adrenergic receptor overexpression. Endocrinology 144: 4097–4105, 2003
20. Graf EM, Heubach JF, Ravens U. The hyperpolarization-activated current If in ventricular myocytes of non-transgenic and b2-adrenoceptor overexpressing mice. Naunyn Schmiedebergs Arch Pharmacol 364: 131–139, 2001
21. Greiser M, Schotten U. Dynamic remodeling of intracellular Ca2 signaling during atrial fibrillation. J Mol Cell Cardiol 58: 134–142, 2013
22. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O’Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309: 896–908, 2013
23. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 345: 1473–1482, 2001
24. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 52: 1574–1580, 2008
25. Keller NR, Diedrich A, Appalsamy M, Tuntrakool S, Lonce S, Finney C, Caron MG, Robertson D. Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity. Circulation 110: 1191–1196, 2004
26. Lang D, Holzem K, Kang C, Xiao M, Hwang HJ, Ewald GA, Yamada KA, Efimov IR. Arrhythmogenic remodeling of b2 versus b adrenergic signaling in the human failing heart. Circ Arrhythm Electrophysiol 8: 409–419, 2015
27. Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, Kalman JM, Kaye DM, Taylor AJ. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 60: 2402–2408, 2012
28. Mavrogeni S, Petrou E, Kolovou G, Theodorakis G, Iliodromitis E. Prediction of ventricular arrhythmias using cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging 14: 518–525, 2013
29. Milan DJ, MacRae CA. Animal models for arrhythmias. Cardiovasc Res 67: 426–437, 2005
30. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial function in transgenic mice overexpressing the b2-adrenergic receptor. Science 264: 582–586, 1994
31. Neilan TG, Coelho-Filho OR, Danik SB, Shah RV, Dodson JA, Verdini DJ, Tokuda M, Daly CA, Tedrow UB, Stevenson WG, Jerosch- Herold M, Ghoshhajra BB, Kwong RY. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. J Am Coll Cardiol Cardiovasc Imaging 6: 944–954, 2013
32. Nguyen TP, Qu Z, Weiss JN. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol 70: 83–91, 2014
33. Nguyen TP, Xie Y, Garfinkel A, Qu Z, Weiss JN. Arrhythmogenic consequences of myofibroblast-myocyte coupling. Cardiovasc Res 93: 242–251, 2012
34. Penela D, Van Huls Van Taxis C, Aguinaga L, Fernandez-Armenta J, Mont L, Castel MA, Heras M, Tolosana JM, Sitges M, Ordonez A, Brugada J, Zeppenfeld K, Berruezo A. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol 62: 1195–1202, 2013
35. Perazzolo Marra M, De Lazzari M, Zorzi A, Migliore F, Zilio F, Calore C, Vettor G, Tona F, Tarantini G, Cacciavillani L, Corbetti F, Giorgi B, Miotto D, Thiene G, Basso C, Iliceto S, Corrado D. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Heart Rhythm 11: 856–863, 2014
36. Pretorius L, Du XJ, Woodcock EA, Kiriazis H, Lin RC, Marasco S, Medcalf RL, Ming Z, Head GA, Tan JW, Cemerlang N, Sadoshima J, Shioi T, Izumo S, Lukoshkova EV, Dart AM, Jennings GL, McMullen JR. Reduced phosphoinositide 3-kinase (p110) activation increases the susceptibility to atrial fibrillation. Am J Pathol 175: 998–1009, 2009
37. Roberts-Thomson KC, Lau DH, Sanders P. The diagnosis and management of ventricular arrhythmias. Nat Rev Cardiol 8: 311–321, 2011
38. Rosker C, Salvarani N, Schmutz S, Grand T, Rohr S. Abolishing myofibroblast arrhythmogeneicity by pharmacological ablation of -smooth muscle actin containing stress fibers. Circ Res 109: 1120–1131, 2011
39. Roubille F, Tardif JC. New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels. Circulation 127: 1986–1996, 2013
40. Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Chaudhary BS, Shapiro S. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 64: 297–305, 1981
41. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res 114: 1004–1021, 2014
42. Striessnig J, Bolz HJ, Koschak A. Channelopathies in Cav1.1, Cav1.3, and Cav1.4 voltage-gated L-type Ca2 channels. Pflugers Arch 460: 361–374, 2010
43. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 95: 754–763, 2004
44. Van Linthout S, Miteva K, Tschope C. Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res 102: 258–269, 2014
45. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast- mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10: 15–26, 2013
46. Xu Q, Dalic A, Fang L, Kiriazis H, Ritchie RH, Sim K, Gao XM, Drummond G, Sarwar M, Zhang YY, Dart AM, Du XJ. Myocardial oxidative stress contributes to transgenic b2-adrenoceptor activation-induced cardiomyopathy and heart failure. Br J Pharmacol 162: 1012–1028, 2010.